London

This research evaluates the use of 3D ultrasound imaging during standard care procedures for patients with liver or kidney tumors. The study focuses on assessing how adding 3D ultrasound guidance can assist during tumor ablation or biopsy. Unlike conventional 2D ultrasound, the 3D method collects multiple 2D images in precise steps to create a detailed three-dimensional view, helping doctors view the tumor area from different angles. This technique is safe, fast, and non-invasive, aiming to improve the accuracy of tumor treatment. During the ablation or biopsy procedures, physicians will use devices that record image data passively while performing standard care. The 3D ultrasound transducer is mounted on a special assembly that moves it precisely to capture successive 2D images. These images are combined by specialized software into a 3D volume for better visualization. The ultrasound images, both 2D and 3D, will be compared to pre- and post-procedure CT scans to confirm that tumors were fully removed or correctly targeted. Participants will be imaged during their liver or kidney ablation or biopsy procedures, provided they are well enough to consent. Researchers will analyze the images collected during the procedure and compare them with CT scans to evaluate treatment accuracy. The main outcome measured is the effectiveness of needle guidance during intervention. The study involves real-time imaging data collection during treatment with no additional invasive procedures required.

Researchers are evaluating the use of hyperpolarized Xenon-129 (129-Xe) MRI alongside pulmonary function testing in adults aged 18 to 85 with diagnosed lung diseases such as asthma, emphysema, COPD, bronchiectasis, sarcoidosis, pulmonary fibrosis, and other related conditions. The study aims to develop tools to assess lung function by measuring the Apparent Diffusion Coefficient (ADC), ventilation defect percent (VDP), and pulmonary gas exchange using 129-Xe MRI technology. Participants will undergo a one to two hour visit involving several procedures: a brief medical history and vital signs check, comprehensive pulmonary function tests including spirometry, plethysmography, and diffusing capacity measurement, proton MRI, specialized 129-Xe MRI using a 3T MR scanner with chest coils, and a low-dose thoracic CT scan. During the MRI, participants will wear hearing protection and have their heart rate and oxygen saturation monitored, with supplemental oxygen available if needed. The CT scan will capture high-resolution images of lung anatomy using the same breath-hold technique as the MRI. Throughout the study visit, participants will perform breath-holds and pulmonary function tests following standardized guidelines to ensure accurate measurements. Researchers will collect data on lung ventilation and structure, analyzing the ventilation defect percent as a primary outcome over five years. Safety measures include monitoring oxygen levels and heart rate during imaging. The study involves a single visit with detailed assessments to better understand lung disease using advanced imaging and physiological testing.

Brachytherapy is an important treatment for gynecological cancers, helping deliver radiation directly to tumors while minimizing exposure to healthy tissue. This research focuses on advanced or recurrent gynecological cancers where interstitial or intra-cavitary brachytherapy is required because standard intrauterine brachytherapy may not be optimal. The study aims to improve needle placement during brachytherapy by using 3D ultrasound imaging to guide needle insertion in real time, potentially avoiding injury to pelvic organs and improving radiation coverage of the tumor. Participants will undergo gynecological brachytherapy, which involves placing radioactive sources near or inside the tumor using a defined template-and-needle system. The study will compare standard needle placement techniques with the use of 3D ultrasound imaging during the procedure. This device-based approach seeks to enhance the accuracy and safety of needle insertion during brachytherapy. Throughout the study, researchers will monitor needle localization accuracy over 16 months. Participants will receive assessments to evaluate the positioning of needles during treatment and ensure optimal radiation delivery. This study involves female patients aged 18 or older with specific gynecological cancers who are offered interstitial or ring and tandem brachytherapy treatment. Safety and treatment effectiveness will be carefully observed during and after therapy.

Researchers are evaluating the use of PET imaging with a tracer called [18F] PSMA-1007 in patients with metastatic clear cell renal cell carcinoma (RCC), a type of kidney cancer. The study focuses on patients aged 18 and older who have confirmed metastatic clear cell RCC and have not yet received systemic therapy. This approach aims to improve detection of hidden metastatic sites, which could influence treatment decisions, as current staging mainly relies on CT or MRI scans. The study is an early phase 1, single-center, open-label feasibility study addressing an important need for better imaging in this disease. Participants will undergo a [18F] PSMA-1007 PET/CT scan in addition to their usual conventional imaging (CT or MRI with contrast) of the chest, abdomen, and pelvis done within 5 weeks before enrollment. The PET/CT scan uses a radioactive tracer that targets PSMA, a molecule highly expressed in clear cell RCC, to detect metastatic lesions. This study does not involve any treatment intervention but focuses on comparing the findings of PET/CT with standard imaging to see if more metastatic sites are found. During the study, participants will be monitored through imaging and biopsy confirmation of metastatic disease. Researchers will measure the number of metastatic lesions detected by the new PET/CT scan within 5 weeks from baseline imaging and evaluate whether this imaging changes the patient's management plan within one month. The total study duration is expected to be about 2 years for recruitment, with assessments focused on imaging results and clinical decision changes. Safety and ability to complete the scan will also be monitored.

Researchers are studying a medicine called enlicitide to reduce low-density lipoprotein cholesterol (LDL-C) in adults with high cholesterol (hyperlipidemia). This trial aims to find out if taking enlicitide together with rosuvastatin, a standard cholesterol-lowering drug, works better than a placebo in lowering LDL-C levels. The study is a Phase 3 trial that is randomized, double-blind, and placebo-controlled to ensure accurate and unbiased results. Participants will receive oral tablets of enlicitide or placebo along with oral capsules of rosuvastatin or placebo. The study compares the effect of enlicitide plus rosuvastatin against placebo to evaluate their impact on LDL-C. The treatment period lasts 8 weeks, during which participants take their assigned medications as directed. During the study, researchers will measure the average percent change in LDL-C from the start of the trial to week 8. Participants will be monitored for safety and any side effects throughout the study. The total participation time includes screening, treatment, and follow-up assessments to evaluate the medicines' effects and safety in adults aged 18 to 64 with hyperlipidemia.

Testicular cancer is a rare adult cancer but the most common solid tumor in young men, with about 90% being germ cell tumors categorized as seminoma or non-seminoma types. About 20% of men with seminoma have clinical stage II disease, with enlarged retroperitoneal lymph nodes but no distant spread. Current treatments for these patients include radiotherapy or chemotherapy, which have high cure rates but can cause significant short- and long-term side effects, including increased risks of heart disease, secondary cancers, and fertility issues. This research aims to evaluate surgery as an alternative treatment for these patients to potentially reduce these risks. The study is testing the use of primary Retroperitoneal Lymph Node Dissection (RPLND), an open bilateral nerve-sparing surgery, for men with testicular seminoma and limited retroperitoneal lymph node metastases. RPLND may allow precise staging, avoid overtreatment, and reserve chemotherapy only for patients who relapse after surgery. The surgery is performed at specialized centers to minimize complications. This is a phase II, single-arm trial focusing on patients with no more than two enlarged lymph nodes, each 3 cm or smaller. Participants will be monitored for at least two years to assess recurrence-free survival. Before surgery, patients undergo imaging and blood tests to confirm eligibility. Researchers will track safety, treatment outcomes, and long-term effects. The study collects detailed data on tumor markers and lymph node status to evaluate the surgery's effectiveness and safety as a primary treatment option for this patient group.

Researchers are evaluating the safety and effectiveness of trontinemab in people aged 50 to 90 with early symptoms of Alzheimer's disease, ranging from mild cognitive impairment to mild dementia. This Phase III clinical trial focuses on those who show evidence of Alzheimer's pathology and have a recent history of cognitive decline. The study aims to measure changes in cognitive function over 72 weeks. Participants will be randomly assigned to receive either intravenous trontinemab or a placebo. The trial is designed as a double-blind, placebo-controlled study, meaning neither participants nor researchers know who receives the active drug or placebo. The treatment period lasts up to 72 weeks, during which participants will undergo various assessments to monitor their cognitive status and safety. During the study, participants will complete clinical tests including cognitive assessments and imaging such as MRI, PET scans, or cerebrospinal fluid analysis to confirm Alzheimer's pathology. A study partner will assist participants as needed. Researchers will track changes from the start of the study through week 72 using tools like the Clinical Dementia Rating. Safety monitoring and adherence to study procedures will also be closely observed throughout the trial.

Researchers are evaluating the effects of AlphaWaveae L-Theanine on mental sharpness and stress relief in healthy adults experiencing moderate stress. The study aims to find out if there is a difference in mental acuity before and after taking a single dose of AlphaWaveae L-Theanine compared to a placebo. Participants include adults aged 18 to 60 with moderate stress levels as measured by a standardized scale. Participants will receive a single capsule of either AlphaWaveae L-Theanine or a placebo, each taken with 250 ml of room temperature water. This is a randomized, triple-blind, placebo-controlled, cross-over trial, meaning each participant will receive both treatments at different times. During the study visits, participants will complete tasks designed to assess cognitive function before and after dosing. Throughout the study, participants will be asked to avoid caffeine, alcohol, vigorous exercise, and certain medications before visits. They will maintain their regular lifestyle habits and complete assessments and diaries. Researchers will measure changes in mental acuity from one hour before to one hour after dosing, monitoring cognitive function and stress. The study involves multiple visits with careful monitoring to ensure safety and adherence over the study period.

Researchers are investigating the effects of Lysoveta, a krill oil-based supplement, on cognitive function in healthy adults aged 50 to 75 who experience self-perceived memory problems. This randomized, triple-blind, placebo-controlled trial aims to determine the differences in changes to episodic, working, and spatial memory between those taking Lysoveta and those receiving a placebo. Participants will complete questionnaires to assess cognitive performance and mood throughout the study. Participants in the study are randomly assigned to receive either Lysoveta capsules, which contain 500 mg of lysophosphatidylcholine-rich oil extract of Antarctic krill, or placebo capsules containing a mix of medium-chain triglyceride oil, maize oil, olive oil, and palm kernel oil. The study is conducted in parallel groups over a period extending to 112 days. During this time, participants will be regularly monitored and asked to avoid certain behaviors such as moderate to vigorous exercise and high caffeine intake before clinic visits. Throughout the 112-day study, participants will be involved in completing various questionnaires and diaries to track cognitive function and mood. Researchers will assess memory changes using the Computerized Mental Performance Assessment System (COMPASS) and monitor safety through medical history reviews and lab tests. The study also requires participants to maintain their usual lifestyle habits and avoid travel across time zones near clinic visits to ensure consistent data collection.

Researchers are evaluating the effects of AMPK Charge+® with and without semaglutide on blood sugar control in adults with prediabetes or Type 2 Diabetes. This randomized, single-blind, controlled clinical trial aims to compare changes in fasting blood glucose, fasting insulin, and hemoglobin A1c (HbA1c) over 84 days between the two treatment groups. Participants include adults with prediabetes or Type 2 Diabetes who meet specific health criteria and are eligible for semaglutide therapy but not currently using it. Participants will be assigned to one of two groups: one group will take AMPK Charge+® alone, consuming one teaspoon (5 mL) on an empty stomach before breakfast and another in the afternoon, holding it in the mouth for 30-90 seconds before swallowing. The other group will follow the same AMPK Charge+® regimen and additionally receive weekly subcutaneous semaglutide injections, starting with 0.25 mg for four weeks, then increasing to 0.5 mg weekly for the remainder of the 84-day study period. During the study, participants will attend clinic visits and complete questionnaires, records, and diaries. Researchers will monitor blood sugar control by measuring fasting blood glucose, fasting insulin, and HbA1c levels from baseline to Day 84. Participants are expected to maintain their usual lifestyle habits throughout the study. Safety and adherence will be assessed during the study period to evaluate the treatments' effects.